Citigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $9
LENZ Therapeutics (LENZ) Stock Fair Value Moves Lower As Analysts Split On VIZZ
LENZ (LENZ) Q3 2026 Earnings Call Transcript
LENZ Therapeutics (LENZ) Stock Rallies As Q3 Results Expose Cash Burn
HC Wainwright & Co. Maintains Buy on LENZ Therapeutics, Lowers Price Target to $16
LENZ Therapeutics Q3 Earnings Call Highlights
LENZ Therapeutics, Inc. (LENZ) Q3 2026 Earnings Call Transcript
TD Cowen Maintains Buy on LENZ Therapeutics, Lowers Price Target to $45
LENZ Therapeutics Q3 2026 Earnings Call Transcript
LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession
LENZ Therapeutics Appoints CFO Dan Chevallard As Interim President, CEO, Effective Dec. 1, Succeeding Eef Schimmelpennink
LENZ Therapeutics Q3 EPS $(0.99) Misses $(0.98) Estimate, Sales $3.384M Miss $4.200M Estimate
LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
TD Cowen Maintains Buy on LENZ Therapeutics, Lowers Price Target to $50
LENZ Therapeutics (LENZ) Stock Fair Value Falls After Analysts Cut VIZZ Launch Expectations
Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $5
LENZ Therapeutics: Below Cash For A Reason
LENZ Therapeutics: Still Speculative But Priced For Disasters
LENZ Therapeutics (LENZ) Stock Sees Fair Value Moves Lower After Analyst Target Cuts
Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $7
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.